

Appl. No.: 10/805,977  
Filed: March 22, 2004  
Amendment Dated October 25, 2006  
Page 2

RECEIVED  
CENTRAL FAX CENTER  
OCT 25 2006

Amendments to the Claims:

1-66. (Canceled)

67. (Previously Presented) A pharmaceutical composition comprising:

(a) an  $\alpha_2\delta$  subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin; and

(b) an antimuscarinic selected from the group consisting of Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride;

and wherein said  $\alpha_2\delta$  subunit calcium channel modulator and said antimuscarinic are in therapeutically effective amounts sufficient to treat a symptom of a lower urinary tract disorder.

68. (Previously Presented) The pharmaceutical composition of claim 67 wherein said  $\alpha_2\delta$  subunit calcium channel modulator is present in an amount from about 50 mg to about 2400 mg, and wherein said antimuscarinic is present in an amount equal to or less than about 5 mg.

69. (Previously Presented) The pharmaceutical composition of claim 67 wherein said  $\alpha_2\delta$  subunit calcium channel modulator is in an amount of about 200 mg.

70. (Previously Presented) The pharmaceutical composition of claim 67 wherein said antimuscarinic is in an amount of about 2.5 mg.

71. (Previously Presented) The pharmaceutical composition of claim 67 wherein said antimuscarinic is in an amount of about 1.25 mg

72. (Previously Presented) The pharmaceutical composition of claim 67 wherein said  $\alpha_2\delta$  subunit calcium channel modulator and said antimuscarinic are present in a ratio from about 1:1 to about 800:1 or from about 1:1 to about 1:800, respectively, based on a fraction of their respective ED<sub>50</sub> values.

LEGA102/30131151v1

Appl. No.: 10/805,977

Filed: March 22, 2004

Amendment Dated October 25, 2006

Page 3

73. (Previously Presented) The pharmaceutical composition of claim 67 wherein said  $\alpha_2\delta$  subunit calcium channel modulator and said antimuscarinic are in a weight/weight ratio of from 1:1 to about 800:1 or from about 1:1 to about 1:800, respectively.

74. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator and said antimuscarinic are formulated for oral, transmucosal, sublingual, buccal, intranasal, transurethral, rectal, inhalation, topical, transdermal, parenteral, intrathecal, vaginal, or perivaginal administration.

75. (Previously Presented) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is associated with benign prostatic hyperplasia or overactive bladder.

76. (Previously Presented) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is urinary frequency.

78. (Previously Presented) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is urinary urgency.

79. (Previously Presented) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is nocturia.

80. (Previously Presented) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is incontinence.

81. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Oxybutynin.

LEGAL02/30131151v1

Appl. No.: 10/805,977

Filed: March 22, 2004

Amendment Dated October 25, 2006

Page 4

82. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Tolterodine.

83. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Propiverine.

84. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Solifenacin monohydrochloride.

85. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Oxybutynin.

86. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Tolterodine.

87. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Propiverine.

88. (Previously Presented) The pharmaceutical composition of claim 67, wherein said  $\alpha_2\delta$  subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Solifenacin monohydrochloride.

LEQAL02/30131151v1

Appl. No.: 10/805,977

Filed: March 22, 2004

Amendment Dated October 25, 2006

Page 5

89. (Previously Presented) A pharmaceutical composition comprising Oxybutynin, wherein said Oxybutynin is in an amount less than about 2.5 mg.

90-95. (Canceled)